aXichem AB (publ) (“aXichem”), that develops and markets analogue industrial compounds, announces that the company has received patent protection for the company's unique product, phenylcapsaicin, for use in the treatment of idiopathic pulmonary fibrosis (IPF).
“This is a strategically interesting patent for aXichem and it strengthens the patent portfolio in an excellent way in an area where the need for effective treatment is great. My hope is that in the future this patent will have commercial significance for the company and that phenylcapsaicin, with its unique properties, will be able to contribute to the more effective treatment of a severe disease”, says Torsten Helsing, CEO of aXichem.
About IPF Idiopathic pulmonary fibrosis (IPF) is a chronic disease characterized by progressive fibrosis (scarring) of the lungs, which means that symptoms worsen over time. The disease picture involves a persistent cough, recurrent lung infections and severe shortness of breath.The background is largely unknown, but for example smoking, viral infections and stomach/intestine-related problems such as gastroesophageal reflux have possible causal links. There is currently no curative treatment for idiopathic pulmonary fibrosis. Treatment generally consists of rehabilitation programs and anti-inflammatory drugs.
The information was submitted, through the care of the contact person, for publication on 27 October, 2022, at 3 PM CEST.